You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hormone positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

Not yet recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +3 more
  • Best Practice
  • +3 more
  • Atlanta, Georgia
  • +3 more
Aug 2, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor Trial in São Paulo (Tamoxifen)

Active, not recruiting
  • Neuroendocrine Tumors
  • +2 more
  • Tampa, Florida
  • +1 more
Jan 13, 2023

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

Breast Cancer Trial in New Brunswick (U-13C-glucose)

Not yet recruiting
  • Breast Cancer
  • New Brunswick, New Jersey
  • +1 more
Feb 16, 2023

Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

Recruiting
  • Early-stage Breast Cancer
  • +4 more
  • Trastuzumab and nelatinib
  • Trastuzumab and Parstuzumab
  • Guangzhou, China
    Sun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023

Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian

Not yet recruiting
  • Hormone-receptor-positive Breast Cancer
  • +3 more
  • Aromatase inhibitor
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Apr 5, 2023

Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)

Recruiting
  • Hormone Receptor-positive Breast Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Musculoskeletal Syndrome Trial in Minneapolis (CBD-dominant, THC dominant)

Recruiting
  • Musculoskeletal Syndrome
  • Minneapolis, Minnesota
    University of Minnesota
Jun 28, 2023

HER2 Negative Breast Cancer Not Immediately Operated Trial (Ribociclib Oral Tablet)

Not yet recruiting
  • HER2 Negative Breast Cancer Not Immediately Operated
  • Ribociclib Oral Tablet
  • (no location specified)
Dec 16, 2022

Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

Not yet recruiting
  • Breast Neoplasms
  • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
  • +2 more
Oct 23, 2023

HER2-positive Breast Cancer, Advanced Breast Cancer Trial in Phoenix, Miami, Boston (Prolonged Overnight Fasting,

Not yet recruiting
  • HER2-positive Breast Cancer
  • Advanced Breast Cancer
  • Prolonged Overnight Fasting
  • +2 more
  • Phoenix, Arizona
  • +2 more
Nov 8, 2023

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Oct 10, 2022

Breast Cancer Trial in Boston (Acupuncture, Usual Care)

Active, not recruiting
  • Breast Cancer
  • Acupuncture
  • Usual Care
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 21, 2022

Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • Tianjin, China
    Tianjin Cancer Hospital
Mar 28, 2023

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    Breast Cancer Trial in Houston (Ra-223 dichloride, Denosumab, Hormone Therapy)

    Completed
    Has Results
    • Breast Cancer
    • Ra-223 dichloride
    • +2 more
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Oct 5, 2021

    Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,

    Not yet recruiting
    • Locoregional Recurrence
    • +2 more
    • (no location specified)
    Jul 18, 2022

    Breast Cancer Trial (Trastuzumab Deruxtecan)

    Not yet recruiting
    • Breast Cancer
    • Trastuzumab Deruxtecan
    • (no location specified)
    Jul 10, 2023

    Breast Cancer Trial in Boston (Pembrolizumab, Nab-Paclitaxel, Biopsy)

    Active, not recruiting
    • Breast Cancer
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Aug 22, 2022

    Real-World Data on First-line Treatment of Hormone

    Recruiting
    • Breast Cancer
      • Porto Alegre, Rio Grande Do Sul, Brazil
        CPO
      Aug 15, 2022

      Breast Cancer Trial in Birmingham (Letrozole, Everolimus, TRC105)

      Active, not recruiting
      • Breast Cancer
      • Birmingham, Alabama
        University of Alabama at Birmingham
      Dec 13, 2022

      Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in Duarte

      Recruiting
      • Anatomic Stage IV Breast Cancer AJCC v8
      • +3 more
      • Duarte, California
        City of Hope Medical Center
      Nov 1, 2022